Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
CagriSema and GLP-1s are turning heads in women's weight management. Women on CagriSema lost 25% of their body weight at 68 weeks across all reproductive stages, while a separate study found that combining hormone therapy (HT) with semaglutide led to significantly greater weight loss in menopausal women. Both findings point to a more personalized approach to obesity care for women.
CagriSema and GLP-1s are reshaping weight management for women at every life stage
Two sets of new findings presented at The Menopause Society's annual meeting highlight how emerging obesity treatments are working across women's reproductive lives. In post hoc analyses of the REDEFINE 1 trial, once-weekly CagriSema (cagrilintide + semaglutide, Novo Nordisk) delivered 25% body weight loss at 68 weeks in women with overweight or obesity — outperforming semaglutide alone (19%), cagrilintide alone (13.4%), and placebo (3%). Weight loss was meaningful across premenopausal, perimenopausal, and postmenopausal women, with premenopausal women trending toward the greatest benefit.
A separate retrospective study of 2,379 midlife women found that combining menopausal hormone therapy (HT) with semaglutide was linked to significantly greater and sustained total body weight loss compared to semaglutide alone — a difference that held up through 15 months of follow-up. The effect was less pronounced with tirzepatide, possibly due to a ceiling effect given that drug's already-robust weight loss profile.
By the Numbers
Why it matters: These findings underscore that women's hormonal status meaningfully influences obesity treatment outcomes. As GLP-1s become mainstream, tailoring therapy to a woman's reproductive stage could unlock better, more sustained results — though experts stress that HT should not be prescribed solely for weight loss.
